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Summary
Many observational studies have reported outcomes after surgical aortic valve replacement (AVR), but there are no recent systematic
reviews and meta-analyses including all available bioprostheses and allografts. The objective of this study is to provide a comprehensive
and up-to-date overview of the outcomes after AVR with bioprostheses and allografts reported in the last 15 years. We conducted a sys-
tematic literature review (PROSPERO register: CRD42015017041) of studies published between 2000–15. Inclusion criteria were observa-
tional studies or randomized controlled trials reporting on outcomes of AVR with bioprostheses (stented or stentless) or allografts, with or
without coronary artery bypass grafting (CABG) or valve repair procedure, with study population size n≥ 30 and mean follow-up length
≥5 years. Fifty-four bioprosthesis studies and 14 allograft studies were included, encompassing 55 712 and 3872 patients and 349 840 and
32 419 patient-years, respectively. We pooled early mortality risk and linearized occurrence rates of valve-related events, reintervention
and late mortality in a random-effects model. Sensitivity, meta-regression and subgroup analyses were performed to investigate the inﬂu-
ence of outliers on the pooled estimates and to explore sources of heterogeneity. Funnel plots were used to investigate publication bias.
Pooled early mortality risks for bioprostheses and allografts were 4.99% (95% conﬁdence interval [CI], 4.44–5.62) and 5.03% (95% CI, 3.61–
7.01), respectively. The late mortality rate was 5.70%/patient-year (95% CI, 4.99–5.62) for bioprostheses and 1.68%/patient-year (95% CI,
1.23–2.28) for allografts. Pooled reintervention rates for bioprostheses and allografts were 0.75%/patient-year (95% CI, 0.61–0.91) and
1.87%/patient-year (95% CI, 1.52–2.31), respectively. There was substantial heterogeneity in most outcomes. Meta-regression analyses
identiﬁed covariates that could explain the heterogeneity: implantation period, valve type, patient age, gender, pre-intervention New York
Heart Association class III/IV, concomitant CABG, study design and follow-up length. There is possible publication bias in all outcomes.
This comprehensive systematic review and meta-analysis provides an overview of the outcomes after AVR with bioprostheses and allografts
reported during the last 15 years. The results of this study can support patients and doctors in the prosthetic valve choice and can be used
in microsimulation models to predict patient outcomes and estimate the cost-effectiveness of AVR with bioprostheses or allografts
compared with current and future heart valve prostheses.
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INTRODUCTION
Heart valve substitutes available for surgical aortic valve replace-
ment (AVR) can be broadly divided into mechanical and biological
valves. Biological valves have the advantages that there is no need
for lifelong anticoagulation medication and that the ticking sound
of mechanical valves is absent. However, disadvantages of bio-
logical valves are a limited durability and a subsequent risk of
reoperation. The use of biological valves for AVR in the USA
increased from 37.7% of all implanted valves during 1998–2001 to
63.6% during 2007–2011 [1].
Biological valves can be divided into bioprostheses (stented or
stentless), allografts and autografts. Stented bioprostheses are the
most frequently implanted biological valves [2]. Stentless bio-
prostheses are presumed to have better haemodynamics than
stented bioprostheses and therefore might prevent prosthesis–
patient mismatch and improve durability [3]. However, long-term
outcomes indicated that the durability was not better than
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expected [3]. Allografts were hypothesized to have improved dur-
ability compared with bioprostheses because they are obtained
from human donors. However, several studies have shown that
the risk of reoperation for structural valve deterioration (SVD) is
comparable or even higher than in bioprostheses [4, 5]. Therefore,
bioprostheses that are readily available might be preferred.
Currently, allografts are predominantly implanted in patients with
acute infective endocarditis with perivalvular lesions [6].
Many observational studies reported the long-term mortality
and occurrence of valve-related events after AVR with biological
valve prostheses. Grunkemeier et al. [7] reviewed the long-term
clinical results of various options for heart valve replacement, based
on publications between 1989 and 1999. There are also several
systematic reviews and meta-analyses that analysed the outcomes of
implantation with speciﬁc bioprostheses across several publications
[8, 9]. However, to our knowledge, there are no recent systematic
reviews and meta-analyses that include all available bioprostheses
and allografts. The objective of this study is to provide up-to-date
estimates of reported outcomes after surgical AVR (especially long-
term mortality, valve-related events and reinterventions) with bio-
prostheses and allografts reported during the last 15 years.
METHODS
Search strategy and selection of studies
This systematic review was conducted according to the PRISMA
guidelines [10] and registered in the PROSPERO register
(CRD42015017041; see Supplementary Material for the PRISMA
checklist). On 17 February 2015, the Embase, Medline, Cochrane,
Pubmed publisher and Google Scholar databases were searched
using keywords regarding aortic heart valve bioprostheses or allo-
grafts and outcomes (search terms are provided in Supplementary
Material). We limited our search to studies that were conducted in
humans and published in the last 15 years (1 January 2000–17
February 2015). This time frame was selected to reﬂect recent out-
comes of AVR. Two researchers (Simone A. Huygens and Mostafa
M. Mokhles) independently reviewed the results on titles and
abstracts to determine whether the study met the inclusion
criteria. In case of disagreement, an agreement was negotiated.
The inclusion criteria were observational studies or randomized
controlled trials (RCTs) reporting on the outcomes of AVR with
bioprostheses or allografts with or without coronary artery bypass
grafting (CABG) or any other valve repair procedure, but excluding
other valve replacements (a maximum of 10% multiple valve repla-
cements in the study population was allowed) with a minimum
study population size n≥ 30 and a minimum mean follow-up
length of 5 years. Studies were excluded if they only reported
results of a propensity-matched population (because of less gener-
alizability of the study population), if the mean or median follow-up
length was not reported, or when they only reported early mortality
risk and no event occurrence, reoperation or late mortality
(because the main aim of this study was to report long-term out-
comes after AVR). In case of multiple publications on the same
patient population, the publication with most follow-up patient-
years was generally included. Exceptions were studies that had
less follow-up patient-years but reported more relevant data than
the overlapping study. Two researchers (Simone A. Huygens and
Mostafa M. Mokhles) jointly decided whether the exception was
justiﬁed. References of selected papers were cross-checked for
other relevant studies.
Data extraction
Microsoft Ofﬁce Excel 2010 (Microsoft Corp., Redmond, WA, USA)
was used for data extraction. Data extraction of all included
studies was performed independently by two researchers (Simone
A. Huygens and Mostafa M. Mokhles). In case of disagreement
about extracted data, an agreement was negotiated. Study design,
valve implantation period (in calendar years) and follow-up dur-
ation (mean and total patient-years) were documented. The fol-
lowing patient characteristics were registered: mean patient age at
the time of surgery, proportion of male patients, concomitant pro-
cedures, pre- and post-intervention New York Heart Association
(NYHA) class, subcoronary allograft valve replacement and endo-
carditis as indication for surgery. If the total number of patient-
years was not provided, mean (or if mean was not reported,
median) follow-up was multiplied by the reported number of
patients. Occurrence of valve-related events, reintervention and
mortality was registered according to the ‘2008 AATS/EACTS/STS
guideline for reporting morbidity and mortality after cardiac
valvular operations’ [11]. The following valve-related events were
registered: early mortality (≤30 days postoperatively or in-hospital),
late mortality (>30 days postoperatively, divided into sudden unex-
pected unexplained death [SUUD], cardiac and valve-related mor-
tality), reintervention (with the reasons for reintervention), early
event occurrence (≤30 days postoperatively or in-hospital) and late
event occurrence (>30 days postoperatively). The included
valve-related events were SVD, non-structural valve dysfunction
(NSD), valve thrombosis, thromboembolism, bleeding and endo-
carditis. In case, an event was reported not to occur, for pooling
purposes it was assumed that 0.5 patient experienced the event.
When the occurrence of valve-related events was only reported as
a linearized occurrence rate (LOR), the number of events that oc-
curred in the study population was calculated by multiplying the
LOR with the total follow-up patient-years. In studies where the
results were reported separately for subgroups (such as pericardial/
porcine or stented/stentless valve prostheses), the weighted mean
of covariates for the total population was calculated and occurrence
rates were summed. Authors were contacted when full text was not
available or to request additional information when follow-up
length and total follow-up patient-years or the proportion of mul-
tiple valve replacements were not reported.
Statistical analyses
Early risks of mortality and valve-related events and late LORs of
valve-related events, reintervention and mortality were calculated
for each individual study and pooled on a logarithmic scale with
the use of the inverse variance method in a random-effects
model. In the random-effects model, the Der Simonian and Laird
method was used for estimating the between-studies variance
[12]. The choice to use a logarithmic scale was veriﬁed by per-
forming Shapiro–Wilk tests on aggregated data on the study level
to test the normality of the distributions in our meta-analysis (i.e.
we did not test the normality of the distributions of the underlying
individual patient data). Leave-one-out sensitivity analyses were
performed to assess the inﬂuence of outliers in the early mortality
risk, late mortality and reintervention rates. The Cochrane Q statis-
tic and I2 statistic were used to assess heterogeneity between
studies. The causes of heterogeneity were explored by performing
univariable meta-regression in the main outcome measures:
early mortality, late mortality, SVD, NSD, valve thrombosis,
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thromboembolism, bleeding, endocarditis and reintervention.
The covariates that were explored for both bioprostheses and allo-
grafts were the start and end of the valve implantation period,
study design, mean follow-up, mean patient age, proportion of
male patients, proportion of patients undergoing concomitant
procedures, proportion of patients undergoing concomitant
CABG and proportion of patients in NYHA class III/IV before
surgery. In addition, valve type (stented or stentless and porcine
or pericardial) was explored in the bioprostheses review, and the
proportion of patients undergoing subcoronary valve replacement
(instead of total root replacement) and endocarditis as indication
for surgery were explored in the allografts review. Subsequently,
we have performed subgroup analyses for stented versus stentless
bioprostheses, retrospective versus prospective study design (in-
cluding RCT) and studies including AVR with concomitant CABG
versus studies that only included AVR without concomitant CABG
to investigate the differences in the outcome measures between
these subgroups. Finally, funnel plots were used to investigate
publication bias.
The meta-analysis, heterogeneity tests, subgroup analysis and
funnel plots were performed in Microsoft Ofﬁce Excel 2010,
Shapiro–Wilk tests using SPSS and leave-one-out sensitivity and uni-
variable meta-regression analyses using open-source meta-analysis
software that uses R as the underlying statistical engine [13].
RESULTS
Literature search
The literature search resulted in 5756 studies on bioprostheses
and 2291 studies on allografts. After applying inclusion and exclu-
sion criteria, 54 studies on bioprostheses and 14 studies on allo-
grafts were included in the systematic review (references provided
in Supplementary Material). The study selection processes are illu-
strated in the ﬂowchart in Fig. 1. We made one exception on the
general rule to include the publication with the most follow-up
patient-years in case of overlapping study populations: Ashikhmina
et al. [14] reported more relevant outcomemeasures (early mortality,
late SVD and late mortality); therefore, this study was included
instead of Said et al. [15] where more follow-up patient-years were
included.
Study characteristics
Tables 1 and 2 provide an overview of studies included in the
present study. In the bioprosthesis group, 55 712 patients were
included, resulting in 349 840 follow-up patient-years. The allograft
group included 3872 patients with 32 419 follow-up patient-years.
The pooled mean follow-up length was 6.7 years for bioprostheses
and 8.5 years for allografts. The pooled mean patient age was 71.8
years for bioprostheses and 48.8 years for allografts. Concomitant
procedures were performed in 51.9% of the patients in studies on
bioprostheses and 28.0% of the patients in studies on allografts. A
common concomitant procedure is CABG, performed in 40.0% of
the patients in studies on bioprostheses and 11.9% of the patients in
studies on allografts.
Study outcomes
The Shapiro–Wilk tests showed that the aggregated data on study
level of the majority of the outcome measures had a normal
distribution after log transformation (note that the distribution of
the underlying individual patient data has not been tested).
Table 3 gives the pooled estimates of early mortality and early
valve-related events, late mortality, late valve-related events and
reintervention for bioprostheses and allografts. Estimates of the
outcome measures for individual studies are provided in
Supplementary Tables 1–8.
Sensitivity analyses
The forest plots of the leave-one-out sensitivity analysis showed that
there were no outliers in the meta-analysis of early mortality risk, late
mortality and reintervention rate in studies on bioprostheses. There
was more variation in the outcome measures in studies on allografts.
Figure 2 shows the forest plot of early mortality risk in studies on allo-
grafts. The other forest plots can be found in Supplementary Material.
Heterogeneity
There was substantial heterogeneity according to the Cochrane Q
and I2 statistics in most outcome measures (Table 3), except for
early valve thrombosis, early endocarditis, late valve thrombosis
and reintervention for valve thrombosis between studies on bio-
prostheses and late cardiac mortality, late bleeding, late endocar-
ditis and reintervention for valve thrombosis and endocarditis
between studies on allografts. The results of the univariable
meta-regression analyses in the outcome measures with substan-
tial heterogeneity between studies are described below and
reported in Supplementary Tables 9–16.
Early mortality. Studies on bioprostheses with a more recent end
of implantation period or studies with a high proportion of males
reported lower early mortality risks. Studies on allografts with a
more recent start of the implantation period report higher early
mortality risks.
Late mortality. Studies on bioprostheses with a relatively old
study population reported higher late mortality rates. In addition,
studies on stentless bioprostheses reported lower late mortality rates
compared with those on stented bioprostheses. Studies on allografts
with a more recent start of implantation period, prospective studies,
studies with a large proportion of concomitant procedures or
studies with a large proportion of patients with pre-intervention
NYHA class III/IV reported lower late mortality rates.
Late valve-related events. Studies on stentless bioprostheses
reported higher SVD rates compared with those that report on
stented bioprostheses. Prospective studies reported lower SVD
rates compared with retrospective studies as did studies with a
higher mean patient age. Studies on allografts with more recent
start or end dates of the implantation period reported lower rates
of SVD. Furthermore, studies with high mean follow-up duration,
high proportion of patients with pre-intervention NYHA class III/
IV or high proportion of patients undergoing subcoronary valve
replacement reported relatively high SVD rates.
Relatively low NSD rates were reported in studies on bioprosth-
eses with a more recent end of implantation period or a high pro-
portion of males.
None of the covariates can explain the heterogeneity in
thromboembolism, bleeding and endocarditis rates between studies
on bioprostheses. Studies on allografts with more recent start or end
dates of the implantation period reported lower thromboembolism
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rates. Furthermore, studies with a high proportion of patients under-
going concomitant CABG, with pre-intervention NYHA class III/IV
or subcoronary valve replacements reported higher thrombo-
embolism rates.
Reintervention. Studies on bioprostheses with a high mean
patient age reported lower rates for reintervention. In addition,
studies on stentless bioprostheses reported higher reintervention
rates compared with those on stented bioprostheses. Prospective
studies on allografts reported lower reintervention rates compared
with retrospective studies.
Subgroup analyses
Table 4 summarizes the pooled estimates of patient and study
characteristics and outcome measures in the subgroups of studies
with stented (n = 37) and stentless (n = 13) bioprostheses.
Noticeable are the differences in the percentage of male patients
Figure 1: Flowchart of study selection (n = bioprostheses|allografts). AVR: aortic valve replacement; MVR: mitral valve replacement; RCT: randomized controlled trial.
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(61.9 vs 55.0% in studies on stented versus stentless bioprostheses,
respectively) and the percentage of concomitant CABG proce-
dures (41.5 vs 28.9% in studies on stented versus stentless bio-
prostheses, respectively). The early mortality risk and late
mortality rate are higher in studies on stented bioprostheses,
whereas the SVD and reintervention rates are higher in studies on
stentless bioprostheses.
The results of the subgroup analyses comparing studies with
retrospective versus prospective designs are reported in
Supplementary Tables 17 and 18. There were no large differences
in outcome measures between retrospective and prospective
studies; therefore, we can safely combine the outcomes of both
types of studies in our meta-analysis.
Supplementary Table 19 presents the results of the subgroup
analysis of studies on bioprostheses without concomitant CABG
(n = 6) versus with concomitant CABG (n = 45). The mean patient
age was higher in the AVR with concomitant CABG group (72.1 vs
67.4 years in AVR with CABG versus AVR without CABG, respect-
ively). The late mortality rate is higher in the studies including con-
comitant CABG (5.83%/patient-year) than in those including only
isolated AVR (4.81%/patient-year). In addition, the rates of late
SVD, bleeding, endocarditis and reintervention are higher in
studies on AVR with CABG than those on AVR without CABG. This
subgroup analysis could not be performed for the studies on allo-
grafts because none of the studies reported outcomes of AVR
without CABG.
Publication bias
The funnel plots showed evidence of possible publication bias in all
outcome measures. Smaller studies with relatively high event rate
estimates seemed to be less likely to be published. Figure 3 shows
the funnel plot of reintervention rate in studies on bioprostheses.
The other funnel plots can be found in Supplementary Material.
DISCUSSION
This is the ﬁrst comprehensive systematic review and meta-
analysis of the outcomes after surgical AVR with bioprostheses and
allografts reﬂecting an overview of reported outcome after bio-
logical AVR in the past 15 years. In this study, we have screened
over 8000 studies and included almost 70 studies from which we
extracted data on the outcomes after AVR. The results of this study
can inform patients and doctors about the expected outcomes
after AVR with bioprostheses or allografts and thereby support
prosthetic valve selection. Furthermore, we will use the results of
this study in microsimulation models to predict individual patient
outcomes and estimate the cost-effectiveness of AVR with bio-
prostheses or allografts. Finally, the results can be used as a bench-
mark for the performance of new alternative interventions for
conventional surgical AVR, such as sutureless valves, transcatheter
aortic valve implantation (TAVI) and, in the future, potentially in
situ tissue-engineered heart valves.
Patient and study characteristics
There are several differences in the patient and study characteris-
tics between the studies on bioprostheses and allografts. Patients
in studies on bioprostheses are older (mean age: 71.8 vs 48.8 years
in studies on bioprostheses versus allografts), they have more con-
comitant CABG (40.0 vs 11.9% in studies on bioprostheses versus
Ta
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allografts) and the mean follow-up duration of studies on bio-
prostheses is shorter than for allografts (6.7 vs 8.5 years in studies
on bioprostheses versus allografts). These differences make it im-
possible to draw meaningful conclusions about the differences in
performance between bioprostheses and allografts based on the
results of this study.
In many institutions, root replacement instead of subcoronary
valve replacement is the technique of choice for implanting allo-
grafts in the aortic position since the mid-1990s [4, 16, 17]. This
trend is also reﬂected in our review where studies with a larger
proportion of root replacement as the surgical technique are gen-
erally studies with a more recent implantation period.
Early mortality
Bioprostheses. The early mortality risk after AVR with bioprostheses
is lower in recent years, which reﬂects improvements in the past
decades in diagnosis and perioperative management of AVR patients.
Our results indicated that studies on bioprostheses with a high
proportion of male patients reported lower early mortality risks
and NSD rates. The relative worse outcomes for women may be
caused by the different preoperative risk proﬁles compared with
men: women undergoing AVR are older, more symptomatic (i.e.
advanced NYHA class), have smaller body surface areas, and more
comorbidities, and more often require emergency operations
than men [18–20]. Delayed presentation of valve problems and/or
later referral of women to cardio-thoracic surgery may explain
some of the differences in risk proﬁle [19]. There is some contro-
versy about the impact of these risk proﬁle differences on the out-
comes after AVR between men and women. Some studies found
an increased early mortality risk in women undergoing AVR with
concomitant CABG [19, 21], but there is no evident association
between gender and early mortality after isolated AVR [18, 21, 22].
Allografts. More recent studies on AVR with allografts reported a
relatively high early mortality risk. A possible explanation is that
the indication for using allografts for AVR has changed over time
from a broad range of patients to mostly complex patients with
Table 3: Pooled estimates of outcomes after AVR with bioprostheses and allografts
Bioprostheses Reported in
no. of studies
I2, % (χ2 P-value) Allografts Reported in
no. of studies
I2, % (χ2 P-value)
Study characteristics
No. of studies 54 14
No. of patients 55 712 3872
Mean follow-up, years ± SD 6.7 ± 4.7 54 8.5 ± 3.0 14
Mean age, years ± SD 71.8 ± 9.3 52 48.8 ± 13.0 13
Male (%) 61.0 48 69.4 13
Concomitant CABG (%) 40.0 51 11.9 11
Early mortality
Early mortality, % 4.99 (4.44–5.62) 48 81 (0.000) 5.03 (3.61–7.01) 14 73 (0.000)
Early valve-related events
SVD, % 0.58 (0.01–25.32) 3 91 (0.000) 0
NSD, % 2 0
Valve thrombosis, % 0.34 (0.15–0.79) 3 0 (0.488) 0
Thromboembolism, % 2.95 (1.55–5.60) 7 92 (0.000) 0
Re-exploration for bleeding, % 4.06 (2.93–5.63) 14 92 (0.000) 1
Endocarditis, % 0.22 (0.07–0.70) 4 36 (0.194) 1
Late mortality
Late mortality, %/year 5.70 (4.99–6.53) 47 99 (0.000) 1.68 (1.23–2.28) 10 86 (0.000)
Cardiac late mortality %/year 2.49 (1.95–3.18) 29 98 (0.000) 1.03 (0.88–1.19) 8 0 (0.760)
Valve-related late mortality, %/year 0.92 (0.74–1.15) 33 94 (0.000) 0.41 (0.29–0.58) 9 51 (0.037)
SUUD, %/year 0.15 (0.09–0.26) 21 90 (0.000) 2
Late valve-related events
SVD, %/year 0.60 (0.47–0.76) 37 93 (0.000) 2.26 (1.02–4.97) 3 90 (0.000)
NSD, %/year 0.20 (0.13–0.32) 20 88 (0.000) 1
Valve thrombosis, %/year 0.04 (0.03–0.07) 13 0 (0.651) 0
Thromboembolism, %/year 1.10 (0.83–1.47) 36 97 (0.000) 0.46 (0.20–1.08) 5 93 (0.000)
Bleeding, %/year 0.44 (0.30–0.65) 31 96 (0.000) 0.15 (0.09–0.25) 3 0 (0.548)
Endocarditis, %/year 0.38 (0.32–0.44) 35 57 (0.000) 0.42 (0.31–0.58) 5 28 (0.236)
Reinterventions
Total, %/year 0.75 (0.61–0.91) 47 95 (0.000) 1.87 (1.52–2.31) 13 80 (0.000)
Valve-related, %/year 0.72 (0.60–0.86) 45 94 (0.000) 1.85 (1.49–2.29) 13 81 (0.000)
SVD, %/year 0.42 (0.33–0.54) 37 92 (0.000) 1.15 (0.77–1.70) 8 90 (0.000)
NSD, %/year 0.11 (0.07–0.17) 28 74 (0.000) 0.13 (0.05–0.32) 7 73 (0.001)
Valve thrombosis, %/year 0.03 (0.02–0.05) 25 0 (0.642) 0.02 (0.01–0.06) 8 0 (0.655)
Endocarditis, %/year 0.19 (0.16–0.23) 31 46 (0.004) 0.27 (0.19–0.38) 9 36 (0.128)
95% CIs of the pooled estimates are provided in parentheses.
Pooled estimates are only reported when ≥3 studies reported the outcome measure.
Total numbers of early and late valve-related events are not reported because few studies reported all valve-related events.
SVD: structural valve deterioration; NSD: non-structural valve dysfunction; SUUD: sudden unexpected unexplained death; CABG: coronary artery bypass
grafting.
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Figure 2: Forest plot of leave-one-out analysis of early mortality risk in studies on allografts. CI: conﬁdence interval.
Table 4: Subgroup analysis stented versus stentless bioprostheses
Stented bioprostheses Reported in no. of studies Stentless bioprostheses Reported in no. of studies
Study characteristics
No. of studies 37 13
No. of patients 44 208 3412
Mean follow-up, years ± SD 6.6 ± 4.9 37 7.4 ± 3.3 13
Mean age, years ± SD 71.9 ± 9.5 35 70.6 ± 8.4 13
Male (%) 61.9 31 55.0 13
Concomitant CABG (%) 41.5 34 28.9 11
Early mortality
Early mortality, % 5.15 (4.43–5.98) 32 4.17 (3.08–5.65) 11
Early valve-related events
SVD, % 0.03 (0.00–0.19) 2 1
NSD, % 2 1
Valve thrombosis, % 0.20 (0.06–0.68) 3 1
Thromboembolism, % 1.41 (0.52–3.81) 5 3.64 (0.40–32.71) 2
Re-exploration for bleeding, % 3.62 (2.53–5.16) 11 6.96 (5.08–9.55) 5
Endocarditis, % 0.10 (0.04–0.24) 3 2
Late mortality
Late mortality, %/year 6.01 (5.10–7.08) 32 4.56 (3.70–5.61) 12
Late valve-related events
Cardiac late mortality %/year 2.31 (1.73–3.09) 19 2.21 (1.50–3.26) 8
Valve-related late mortality, %/year 0.93 (0.74–1.16) 24 0.89 (0.43–1.84) 8
SUUD, %/year 0.19 (0.11–0.35) 16 0.05 (0.02–0.18) 5
SVD, %/year 0.48 (0.38–0.62) 26 1.10 (0.65–1.86) 9
NSD, %/year 0.16 (0.10–0.27) 18 0.33 (0.06–1.77) 3
Valve thrombosis, %/year 0.04 (0.02–0.07) 11 2
Thromboembolism, %/year 1.04 (0.83–1.30) 26 0.99 (0.66–1.47) 8
Bleeding, %/year 0.43 (0.32–0.57) 21 0.31 (0.14–0.70) 7
Endocarditis, %/year 0.34 (0.27–0.43) 25 0.43 (0.33–0.58) 8
Reinterventions
Total, %/year 0.65 (0.51–0.83) 34 1.06 (0.77–1.46) 12
Valve-related, %/year 0.63 (0.51–0.78) 32 0.99 (0.69–1.41) 12
SVD, %/year 0.33 (0.24–0.44) 24 0.82 (0.57–1.19) 11
NSD, %/year 0.08 (0.05–0.13) 19 0.27 (0.14–0.50) 9
Valve thrombosis, %/year 0.03 (0.02–0.04) 19 0.04 (0.01–0.10) 8
Endocarditis, %/year 0.16 (0.13–0.20) 22 0.24 (0.15–0.37) 9
95% CIs of the pooled estimates are provided in parentheses.
Pooled estimates are only reported when ≥3 studies reported the outcome measure.
Total numbers of early and late valve-related events are not reported because few studies reported all valve-related events.
SVD: structural valve deterioration; NSD: non-structural valve dysfunction; SUUD: sudden unexpected unexplained death.
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active endocarditis [4, 6]. Indeed, in this review, three relatively
recent studies with endocarditis as indication for surgery in more
than 40% of the patients reported relatively high early mortality
risks [23–25].
Early valve-related events
Bioprostheses. The results of our study reﬂect low risks for most
early events after AVR with bioprostheses, with bleeding and
thromboembolism being most common. They reﬂect that AVR is
a safe procedure; however, these low risks can also reﬂect
underreporting since most included studies did not report early
event occurrence. Of note, although we reported an early event
risk for endocarditis during the ﬁrst postoperative month, the risk
of experiencing endocarditis still increases until 6 months
postoperatively after which it reaches a plateau close to zero [26].
Allografts. Occurrences of early valve-related events after AVR
with allografts were not or rarely reported.
Late mortality
This review nicely illustrates that late deaths after AVR are only in
part cardiac, and valve-related and SUUDs comprise only part of
cardiac mortality. The remaining non-valve-related cardiac mor-
tality can be ascribed to the excess mortality risk in patients after
AVR, due to underreporting of valve-related events and left ven-
tricular dysfunction associated with heart valve disease [27–29].
Bioprostheses. Our meta-regression conﬁrmed the commonly
reported ﬁnding that higher patient age at implant is associated
with a higher risk of late mortality after AVR with bioprostheses
[14, 30, 31].
Allografts. For allografts, there was a lower late mortality in the
studies with a high proportion of patients with pre-intervention
NYHA class III/IV. This seems counterintuitive, but might be
explained by the fact that the indication in most patients receiving
allografts is endocarditis, which is often accompanied by a
worse pre-intervention NYHA class. Mokhles et al. [32] have
shown that the late mortality of hospital survivors after AVR for
endocarditis is comparable with the general population. This
indicates that although these patients have a worse functional
class before surgery, after surgery their endocarditis is cured and
their mortality hazard returns to that of the general population.
This can also explain why the late mortality rate is lower in studies
on allografts with a more recent implantation period; in recent
years, the indication for using allografts for AVR is often
endocarditis [4, 6]. Indeed, three relatively recent studies in this
review, where the indication for surgery was endocarditis in more
than 40% of the patients, reported relatively low late mortality
rates [23–25]. Furthermore, the low mean age of two studies with a
high proportion of concomitant procedures [33, 34] might explain
why studies with a high proportion of concomitant procedures
report lower late mortality rates.
Surprisingly, prospective studies on allografts reported lower
late mortality rates than retrospective studies. This observation is
probably caused by more common use of prospective design in
more recent years. Indeed, three ‘old’ retrospective studies (studies
where the implantation period ended before 2000) [35–37] in this
review report relatively high late mortality rates.
Late valve-related events
Bioprostheses. For bioprostheses, the most commonly reported
late valve-related event was not SVD but thromboembolism,
reﬂecting the advanced age of the patient population and the
common occurrence of atrial ﬁbrillation in this age group. The
occurrence of SVD was less than 1% per year and more common
in studies with a lower mean patient age, which conﬁrms previous
observations [26].
Prospective studies on bioprostheses reported lower SVD rates
compared with retrospective studies. This was unexpected because
one would expect that prospective studies report higher SVD rates
because of more accurate patient follow-up. The most likely ex-
planation for this counterintuitive observation is the more common
use of prospective study design in more recent years which results in
relatively short follow-up periods, while the occurrence of SVD
increases over time [26].
Allografts. For allografts, SVD was the most commonly occurring
late valve-related event. In this review, the occurrence of endocarditis
after AVR is low. This is remarkable because the indication for AVR
with allografts is often endocarditis. These results conﬁrm that
allografts have a good resistance to infection.
In the meta-regression, several associations were observed
related to late occurrence of different valve-related events after
allograft AVR. However, given the observational design of studies
included in the review, the small number of studies reporting late
valve-related events after allograft AVR and the low event occur-
rence rates; these associations should be interpreted cautiously
and will not be further discussed here.
Reinterventions
Bioprostheses. As would be expected, valve-related reinterventions
in bioprostheses studies showed low occurrence rates and were
usually for SVD, whereas endocarditis and NSD were less common
indications. Studies with a relatively old patient population reported
Figure 3: Funnel plot of the total reintervention rate in studies on bioprostheses.
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lower reintervention rates. This is in accordance with previous
reports that show that older patients are less likely to be reoperated
on [17, 38, 39].
Allografts. Valve-related reinterventions in allografts were most
often for SVD, and to a lesser extent for NSD or endocarditis.
Prospective studies on allografts reported lower reintervention rates
compared with retrospective studies. The effect is probably caused
by the more common use of prospective study design in more
recent years. Indeed, ‘old’ retrospective studies in this review report
slightly higher reintervention rates.
Stented versus stentless bioprostheses
Although it should be noted that in stented bioprostheses studies,
the proportion of males is higher, as is the proportion of patients
undergoing concomitant CABG, the results of the present study indi-
cate that early mortality risk and late mortality rate appear lower in
studies on stentless bioprostheses compared with stented bioprosth-
eses. In contrast, we found that SVD and reintervention rates appear
higher in studies on stentless bioprostheses compared with stented
bioprostheses. The observed lower late mortality rate in stentless
bioprostheses is in accordance with the hypothesis that the haemo-
dynamic superiority of stentless bioprostheses results in survival
beneﬁts compared with stented bioprostheses [3], but may also be
the result of patient selection. The lower late mortality rate in stent-
less bioprosthesis studies makes it difﬁcult to directly compare the
durability of stentless with that of stented bioprostheses as the risk of
death competes with the risk of SVD and reintervention.
Concomitant coronary artery bypass grafting
Many studies included AVR with concomitant CABG and there-
fore, the results of our study do not reﬂect the outcomes after iso-
lated AVR. To explore the inﬂuence of including studies reporting
on outcomes of AVR with concomitant CABG (in a proportion of
the patient population), we have performed a subgroup analysis in
the studies on bioprostheses comparing the outcomes of studies
including and excluding concomitant CABG. This subgroup analysis
showed that there are differences in the outcomes of AVR with or
without CABG. However, the differences were not statistically signiﬁ-
cant (i.e. the CIs of the subgroups overlapped). Furthermore, con-
comitant CABG is a common concomitant procedure with AVR and
therefore, the results presented in our study are relevant for clinical
practice.
Limitations
First, inherent limitations of meta-analyses and combining data
from (retrospective) observational studies should be taken into
consideration [40]. Secondly, selection bias (of patients included in
the studies) might have inﬂuenced the study outcomes due to the
nature of observational studies (i.e. no randomized allocation of
patients to treatment options). Thirdly, publication bias may have
potentially led to underestimation of the pooled estimates when
studies with relatively poor outcomes are not published. Fourthly, by
reporting LORs, we assumed a constant hazard for the valve-related
events and late mortality, while in fact the distributions of these
events are time-related [26]. Fifthly, initially we wished to provide
separate results for different age groups. However, this was not pos-
sible because most studies included patients of all ages. Finally, there
was substantial heterogeneity between studies in most outcome
measures, which may potentially lead to inaccurate results. However,
we pursued a thorough examination of possible sources of hetero-
geneity using univariable meta-regression analysis and we identiﬁed
several covariates that may explain the heterogeneity between
studies in the outcome measures. We deliberately did not perform
multivariable meta-regression analysis because the underlying data
were based on observational studies.
CONCLUSION
This comprehensive systematic review and meta-analysis provided
an overview of the outcomes after surgical AVR with bioprostheses
and allografts during the last 15 years. The results of this systematic
review and meta-analysis can support patients and doctors in the
prosthetic valve choice and can be used in microsimulation
models to predict patient outcomes and estimate the cost-
effectiveness of AVR with bioprostheses or allografts compared
with current and future heart valve prostheses.
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